A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells

February 2016

Cancer Letters 2016, 371:240.


This preclinical study shows that NEO212 can effectively kill brain tumor stem cells. Within a tumor, the stem cells represent the most treatment-resistant part of the tumor tissue; at the same time, they are the most important cells to target during therapy, because they constitute a constant source of new malignant cells that replenish the tumor tissue. The discovery that NEO212 can kill these cells, while sparing normal brain cells, has great clinical value, because killing the tumor stem cells is expected to cut off the supply of new tumor cells.

Comments are closed.